Newly designated human antibody prevents malaria in mice

                  

Malaria, a mosquito spread disease cause by deadliest parasite, Plasmodium falciparum affect around 430000 deaths each year, primarily among young children in sub- Saharan Africa is a very dangerous and broad-spectrum infection worldwide. There is no such highly effective; long lasting vaccine had developed to cure malaria. Currently investigators team at the National Institute of Allergy and Infectious Diseases (NIAID) have isolated the antibody called CIS43, from the blood of a volunteer who had received an experimental vaccine made from weakened malaria parasites (PfSPZ Vaccine-Sanaria). In two different models of malaria infection in mice, it was found that the antibody CIS43 was highly effective at preventing malaria infection. CIS43 could be developed as a prophylactic measure that prevents infection for several months after administration. Such type of prophylactic antibody can be useful for tourists, health care workers, military personnel or others who travel to areas with high chances of malaria. If this antibody prevents malaria infection for up to six months, it might be combined with antimalarial drugs and be arranged as part of mass drug administration efforts that could eradicate the infection in malaria-endemic regions.

CIS43 the newly invented antibody revealed its workings by binding to a specific site called the epitope of a parasite surface protein. This epitope occurs only once along the length of the surface protein. In addition, this CIS43-binding epitope is remaining unspoiled across 99.8 percent of all known strains of P. falciparum, making it a striking target for next-generation experimental malaria vaccines designed to provoke production of this neutralizing antibody. Researchers are planning to access the safety and protective efficiency of the newly discovered CIS43 antibody this year in controlled of human malaria infection.

New Research provide the basic information regarding the future testing in human to determine whether this antibody CIS43 can provide protection against malaria and may help in vaccine design. Bacterial diseases 2018 is a medium for discussing among delegates, scientists, speakers, researchers worldwide on emerging areas like this antibody and how it can be useful for human to get cure from this deadliest parasite. Researchers can represent their views and their emerging research fronts in the Bacterial diseases 2018.